Obstructive sleep apnea has long been framed, both in research and in clinical practice, as a disease that mainly strikes overweight, middle-aged men. But the hormonal shifts of menopause — falling estrogen and progesterone, both of which help maintain upper airway muscle tone during sleep — make postmenopausal women one of the fastest-growing and most underdiagnosed groups of sleep apnea patients. New data presented October 20 at the CHEST 2026 annual meeting in Phoenix suggest that an investigational oral drug for the condition may work unusually well in exactly this population.
A Post Hoc Look at Two Pivotal Trials
The analysis, conducted by Apnimed, pooled data from its two Phase 3 trials of AD109 — a once-daily combination of the antimuscarinic aroxybutynin and the norepinephrine reuptake inhibitor atomoxetine, designed to restore upper airway muscle activation during sleep without the mask or hose of CPAP. The pooled dataset included 492 postmenopausal women (262 on AD109, 230 on placebo) and 807 nonmenopausal participants (391 on AD109, 416 on placebo), drawn from the 26-week SynAIRgy trial and the 51-week LunAIRo trial.
The company's post hoc comparison found that AD109 reduced the hypopnea-defined apnea-hypopnea index (AHI4) by a geometric mean of 59.6% in postmenopausal women, compared with a 44.0% reduction in nonmenopausal participants on the same drug. Hypoxic burden — a measure of how much and how long blood oxygen dips during sleep — fell by 69.8% in the postmenopausal group, according to the presentation, reported by HCPLive.
A Bigger Share of Patients Hit the Treatment Target
Beyond the average reduction, the responder analysis is notable. Nearly half of postmenopausal women taking AD109 achieved at least a 50% drop in their AHI, compared with 20.2% of those on placebo. Among nonmenopausal participants, about a third of those on AD109 hit that same 50% threshold, versus 18% on placebo. In other words, postmenopausal women were not just improving — they were more likely than their younger counterparts to cross the threshold clinicians typically consider a meaningful treatment response.
Dry mouth, a known side effect tied to AD109's antimuscarinic component, was more common in postmenopausal women — reported by close to half of that group, compared with about a third of nonmenopausal participants — though the companies characterized the drug's overall safety profile as consistent with prior trials.
Why Menopause May Change the Biology of Sleep Apnea
The finding fits a broader pattern researchers have documented for years: sleep apnea prevalence and severity rise sharply after menopause, even adjusting for weight gain, as declining sex hormones reduce the neuromuscular tone that keeps the upper airway open during sleep. That same hormonal mechanism may be part of why a drug designed to pharmacologically boost airway muscle activation produces a larger relative benefit once natural hormonal support has receded. Apnimed's researchers framed the results as hypothesis-generating rather than conclusive, calling for further analysis of how menopausal status should factor into AD109 treatment decisions.
AD109 is not yet approved. Apnimed's New Drug Application is currently under FDA review, with a target decision date of February 28, 2027. If approved, it would be the first oral pill specifically for obstructive sleep apnea, offering an alternative for the large share of patients who cannot tolerate or refuse CPAP therapy.
What This Means for Patients
For postmenopausal women who have struggled with CPAP compliance — or who were never properly screened for sleep apnea in the first place because it wasn't seen as "their" disease — this subgroup analysis is an early signal that a pill-based option could be especially effective once it reaches the market. It also reinforces a message sleep clinicians have been pushing for years: menopause itself is a legitimate, hormonally driven risk factor for sleep apnea, and women experiencing new or worsening snoring, witnessed pauses in breathing, or unexplained daytime fatigue around the menopausal transition should ask their doctor about a sleep evaluation rather than assuming new sleep troubles are "just menopause."
